Krop IE - Search Results

1

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.

Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff R. Rimawi MF, et al. Among authors: krop ie. Breast Cancer Res Treat. 2018 Feb;167(3):731-740. doi: 10.1007/s10549-017-4533-9. Epub 2017 Nov 7. Breast Cancer Res Treat. 2018. PMID: 29110152 Free PMC article. Clinical Trial.

2

Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors.

Krop I, Maguire P, Lahti-Domenici J, Lodeiro G, Richardson A, Johannsdottir HK, Nevanlinna H, Borg A, Gelman R, Barkardottir RB, Lindblom A, Polyak K. Krop I, et al. Cancer Res. 2003 May 1;63(9):2024-7. Cancer Res. 2003. PMID: 12727813

3

Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.

Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL. Guix M, et al. Among authors: krop ie. J Clin Oncol. 2008 Feb 20;26(6):897-906. doi: 10.1200/JCO.2007.13.5939. Epub 2008 Jan 7. J Clin Oncol. 2008. PMID: 18180460 Clinical Trial.

4

Ten years of HER2-directed therapy: still questions after all these years.

Krop IE, Winer EP. Krop IE, et al. Breast Cancer Res Treat. 2009 Jan;113(2):207-9. doi: 10.1007/s10549-008-0041-2. Epub 2008 May 8. Breast Cancer Res Treat. 2009. PMID: 18463974 No abstract available.

5

Mechanisms of trastuzumab resistance in breast cancer.

Tolaney SM, Krop IE. Tolaney SM, et al. Among authors: krop ie. Anticancer Agents Med Chem. 2009 Mar;9(3):348-55. doi: 10.2174/1871520610909030348. Anticancer Agents Med Chem. 2009. PMID: 19275526 Review.

6

Managing trastuzumab-resistant breast cancer.

Krop I. Krop I. Clin Adv Hematol Oncol. 2009 Feb;7(2):108-10. Clin Adv Hematol Oncol. 2009. PMID: 19367251 No abstract available.

7

Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists.

Yang XH, Flores LM, Li Q, Zhou P, Xu F, Krop IE, Hemler ME. Yang XH, et al. Among authors: krop ie. Cancer Res. 2010 Mar 15;70(6):2256-63. doi: 10.1158/0008-5472.CAN-09-4032. Epub 2010 Mar 2. Cancer Res. 2010. PMID: 20197472 Free PMC article.

8

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA. Krop IE, et al. J Clin Oncol. 2010 Jun 1;28(16):2698-704. doi: 10.1200/JCO.2009.26.2071. Epub 2010 Apr 26. J Clin Oncol. 2010. PMID: 20421541 Clinical Trial.

9

Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer.

Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, Cibas ES, Jänne PA, Krop IE. Flores LM, et al. Among authors: krop ie. Br J Cancer. 2010 May 11;102(10):1495-502. doi: 10.1038/sj.bjc.6605676. Br J Cancer. 2010. PMID: 20461092 Free PMC article.

10

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.

Mayer EL, Krop IE. Mayer EL, et al. Among authors: krop ie. Clin Cancer Res. 2010 Jul 15;16(14):3526-32. doi: 10.1158/1078-0432.CCR-09-1834. Clin Cancer Res. 2010. PMID: 20634194 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

227 results

Search Page